SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun to launch Ranitidine 75mg OTC Tablets

08 Mar 2018 Evaluate

Strides Shasun is planning to launch Ranitidine Tablets USP, 75 mg (OTC) for the US markets. The new launch will further strengthen Strides’ Ranitidine portfolio that now includes Ranitidine Tablets 150 mg and 300 mg in the Rx space and Ranitidine Tablets 75 mg and 150 mg in the OTC space. The company is already a key player with 32% share of the US Rx market for Ranitidine. According to IRI data, the US OTC market for Ranitidine Tablets, which is the generic form of the popular brand Zantac, is approximately $200 million.

This is the second product approval from company’s 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV’s Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.

The company has 82 cumulative ANDA filings with USFDA (including its JV with Vivimed) of which 51 ANDAs have been approved as of date and 31 are pending approval.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.


Strides Pharma Scien Share Price

995.90 -4.80 (-0.48%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×